Drugs for asthma, pulmonary artery hypertension and non-small cell lung cancer have received recommendations for PBS listing from the Pharmaceutical Benefits Advisory Committee (PBAC). At its July 2020 meeting, the PBAC recommended the following listings: Atectura Breezhaler: listing of the fixed dose combination (FDC) of mometasone furoate with indacaterol for the maintenance treatment of asthma. ...
4 respiratory therapies get PBAC recommendations
By Michael Woodhead
25 Aug 2020